This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
Huge news in APOL1 nephropathy - ten tweets to fill you in here:
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) May 12, 2023
✳️10 tweets #NephJC catch-up ✳️
On 4/25-26, we discussed the phase II study examining inaxaplin treatment, a small molecule inhibitor, in APOL1 nephropathy. This is the first drug specifically targeting this disease.
Join us here for the recap! pic.twitter.com/LApAHkYn10
Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
Welcome to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) April 28, 2023
✳️10 tweets #NephJC catch-up ✳️
On 3/28-29, #NephJC reviewed the MAIN trial (Mycophenolate monotherapy in IgA Nephropathy). Here are some pearls from the chat ⬇️ pic.twitter.com/RUepFSEwXx
Ten Tweet round up of exciting CAR T trial in patients with SLE discussed last month - check it out while you can!
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) November 18, 2022
✳️ 10 tweets #NephJC catch-up ✳️
Here’s a recap of our 25th Oct #NephJC discussion on ‘Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus’ - better late than never!
Check out the paper at https://t.co/HxTcVC3PtH pic.twitter.com/y7o71HUPiZ
Did you miss the TESTING reboot discussion? No worries, we have you covered here:
Welcome to #TenTweetNephJC where we will be discussing the largest randomized, placebo controlled trial of steroid treatment in IgA nephropathy patients.
— Nephrology Jrnl Club (@NephJC) June 21, 2022
✳️ 10 tweets #NephJC catch-up ✳️ pic.twitter.com/kRdt91F8gq
